Our partner company, Plasmagen Biosciences, a biopharmaceutical company focused on blood plasma-derived pharmaceutical products for India and emerging markets, has raised INR 225 crores, led by UK based Artian Investments, prominent public market investor Ashish Kacholia, pharmaceutical entrepreneurs Anurag Bagaria and Dushyant Patel and other notable HNI investors along with continued participation from our India Ventures team and F-Prime Capital.

With this round, the Bengaluru based company has raised close to INR 400 crores in total so far and plans to use the fresh capital to expand its presence internationally, develop products and fund working capital requirements.

Speaking about the fundraise, Vinod Nahar, Founder & Managing Director, PlasmaGen Biosciences said, “This latest funding strengthens our position as market leaders in our mission to be a trusted and leading Indian biopharmaceutical company, dedicated towards improving the health and quality of life of patients. We’re grateful to all our investors for their partnership as we continue to improve the accessibility of blood-plasma derived products for patients in India and emerging countries.”

Earlier this year, Plasmagen inaugurated a new manufacturing facility for blood plasma-derived protein therapeutics in Kolar, Bengaluru - India’s first plasma manufacturing facility by a pure-play, end-to-end blood-plasma company and only the fifth plasma fractionation facility in India. It has the initial capacity to process 5,00,000 litres of plasma annually and will produce multiple plasma products like albumin, immunoglobulins and coagulation factors. It will significantly improve the demand-supply gap for blood-plasma derived products, and at affordable prices. Additional capacity has been incorporated into the design, allowing PlasmaGen to expand its product portfolio in the future.

For more details read the press coverage here